



LUND UNIVERSITY  
Faculty of Medicine

---

# LUP

*Lund University Publications*

Institutional Repository of Lund University

---

This is an author produced version of a paper published in *Molecular Genetics and Metabolism*. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:  
Maria Hietala, Maria Henningson, Therese Törngren,  
Håkan Olsson, Helena Jernström

"Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families."

*Molecular Genetics and Metabolism* 2010 Nov

<http://dx.doi.org/10.1016/j.ymgme.2010.09.006>

Access to the published version may require journal subscription.

Published with permission from: Elsevier

# Androgen Receptor htSNPs in Relation to Androgen Levels and OC Use in Young Women from High-Risk Breast Cancer Families

Maria Hietala<sup>1</sup>, Maria Henningson<sup>1</sup>, Therese Törngren<sup>1</sup>, Håkan Olsson<sup>2</sup>, Helena Jernström<sup>1\*</sup>

1) Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, 221 85 Lund Sweden

2) Department of Oncology and Cancer Epidemiology, Clinical Sciences, Lund University, Barngatan 2B, 221 85 Lund Sweden

## Correspondence:

Helena Jernström, Department of Oncology, Clinical Sciences, Lund University

Barngatan 2B, SE-221 85 Lund, Sweden,

Fax: +46-46-14 73 27 E-mail: [helena.jernstrom@med.lu.se](mailto:helena.jernstrom@med.lu.se)

## Abstract

High testosterone levels have been associated with breast cancer. *BRCA1* may function as an androgen receptor (AR) co-regulator. We aimed to examine *AR* haplotype-tagging single-nucleotide polymorphisms (*AR* htSNPs) and diplotypes in relation to *in vivo* androgen levels, combined OC use, CAG and GGC genotypes, and *BRCA1/2/X* family status in 269 young healthy women from breast cancer high-risk families and 56 additional *BRCA1/2* mutation carriers. Testosterone, androstenedione, dehydroepiandrosterone sulfate and body constitution were measured on cycle days 18-23. Six *AR* htSNPs, and CAG and GGC repeat lengths were genotyped. Most OC users had lower androgen levels than non-users (all  $P_s < 0.0001$ ). Rare variant diplotypes were associated with higher testosterone levels in OC users than in non-users ( $P_{\text{interaction}} = 0.011$ ). The interaction remained after adjustment for family clustering. Neither individual *AR* htSNPs nor other diplotypes were significantly associated with androgen levels and did not tag for CAG or GGC genotypes. In the first included woman from each family, the odds of having the most common diplotype was lower in *BRCA1* families compared to other families OR 0.41 (95%CI 0.22-0.78). In conclusion we found few associations between *AR* htSNPs or diplotypes and androgen levels in women. Diplotypes cannot replace genotyping of microsatellites CAG or GGC. Since testosterone levels are not affected the same way by combined OC use among all women, young women who have higher testosterone levels during combined OC use may belong to the subgroup of women who will not be helped by combined OCs for treatment of androgen dependent conditions and may be at higher risk for early-onset breast cancer. Whether these women can be identified with *AR* genotyping needs to be confirmed in an independent cohort.

**Key words:** androgen receptor polymorphisms / androgens / oral contraceptives / *BRCA* / premenopausal women

## Introduction

Androgens play an important role in several conditions affecting women, such as acne, hirsutism, alopecia, oligo-amenorrhea [1, 2] and breast cancer [3]. Approximately 25% of testosterone in women is produced in the ovaries, 25% in the adrenal glands and 50% via conversion of the proandrogens dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), and androstenedione in the peripheral tissues [4, 5]. Circulating testosterone can be converted to dihydrotestosterone (DHT) and estradiol. High testosterone, androstenedione and DHEAS levels have been linked to higher breast cancer risk in premenopausal [3, 6, 7] as well as postmenopausal women [3, 8-10]. However, others have not found an increased breast cancer risk with high androgen levels [11]. Both growth inhibitory and stimulatory effects of androgens have been described in human breast cancer cell lines [4, 12]. Testosterone and DHT exert their effect in the mammary tissue via the androgen receptor (AR) and the effects depend on the type and dose of the androgen hormone, the structure of the AR, and the expression of co-regulators [4], as well as possible interactions between testosterone and estrogen, progesterone and insulin-like growth factor (IGF-I) [12, 13].

Breast cancer is diagnosed in approximately 7000 women in Sweden every year [14]. Hereditary factors are believed to play a role in 5-10% of breast cancers [15-17]. Mutations in the dominant, high-penetrance genes *BRCA1* and *BRCA2* confer a substantially increased risk of developing breast and ovarian cancer [15, 16]. In non-*BRCA1/2* families, referred to as *BRCAX* families, the pathogenesis is believed to depend on polymorphisms in several low-penetrance and high-prevalence genes, modified by environmental factors [15, 17, 18]. The *BRCA1* may function as an AR co-regulator and enhance the AR transactivation in breast cancer cells [19].

One risk modifying, low-penetrance, high-prevalence susceptibility gene might be the *AR* [16, 20], located on the X-chromosome. The AR protein is located in steroid hormone-sensitive cells, such as the normal breast epithelium, and in the majority of breast cancer cells [11, 12]. It functions as a transcription regulator [11]. Two highly polymorphic microsatellites located on the N-terminal of the AR, a polyglutamin tract encoded by (CAG) repeats and a polyglycine tract encoded by (GGT)<sub>3</sub>GGG(GGT)<sub>2</sub>(GGC)<sub>n</sub> repeats have been studied in relation to testosterone levels in women [21-24]. The CAG and GGC repeat lengths have also been studied in relation to breast cancer, both in the general population [20, 25-27] as well as among women from high-risk families [28]. However, the results have been inconsistent. The risk associated with different CAG and GGC repeat lengths might be modified by OC use [20, 24]. OC use lowers testosterone levels in most, but not all women [24, 29]. Moreover, OC use is associated with higher breast cancer risk in the general population [30], as well as in women from high-risk families [31, 32]. It is possible that young women who have higher testosterone levels during OC use belong to the subgroup of women who are at higher risk for early-onset breast cancer if they use OCs. Genetic polymorphisms in the *AR* other than the CAG and GGC microsatellites may also modify androgen levels and breast cancer risk. Cox *et al.* recently studied *AR* haplotype-tagging single-nucleotide polymorphisms (htSNPs), haplotypes and CAG repeat in a large case control study, but none of the *AR* haplotypes, individual htSNPs or the CAG repeat lengths were associated with breast cancer risk [33]. To our knowledge, *AR* htSNP diplotype data have never been examined in relation to *in vivo* androgen levels, combined OC use, CAG and GGC genotype or *BRCA1/2* and *BRCAX* family status among young women with a family history of breast cancer.

We aimed to examine AR htSNP diplotype data in relation to *in vivo* androgen levels, combined OC use, CAG and GGC genotypes and *BRCA1/2* and *BRCAX* family status. The first aim was to analyze the frequency of the AR htSNPs, which have been identified to capture 95% of the haplotypes found in Swedish men in the Cancer Prostate in Sweden (CAPS) study [34]. The second aim was to determine whether any specific AR htSNP diplotypes were related to testosterone, androstenedione and DHEAS levels among all women as well as stratified according to current use of combined OCs. The third aim was to determine whether AR htSNP diplotypes were associated with AR microsatellite CAG and GGC repeat length genotypes. The fourth aim was to determine whether any specific diplotypes co-segregated within *BRCA1/2* and *BRCAX* families.

## Materials and Methods

### *Study population*

Eligible participants had to belong to high-risk breast cancer families and be either known *BRCA1* or *BRCA2* mutation carriers or first or second-degree relatives of a breast cancer case or a known male or female *BRCA1* or *BRCA2* mutation carrier. We considered a family to be at high-risk for breast cancer if at least three first-degree relatives were diagnosed with breast cancer and one diagnosed before age 50; two first-degree relatives with breast cancer and one diagnosed before age 40; or one first-degree relative with breast cancer diagnosed before age 30. Participants had to be 40 years of age or younger and be menstruating. Exclusion criteria were a previous prophylactic mastectomy, a bilateral oophorectomy or any type of cancer diagnosis at the time of enrollment between 1996 and 2006. Two hundred and sixty nine young women from 161 breast cancer high-risk families volunteered to participate in this study, and 267 of them consented to genetic testing of single nucleotide polymorphisms (SNPs). Potential participants were identified from charts and pedigrees from the Lund Oncogenetic Clinic. Individuals who themselves had been to the Clinic were contacted, first by a letter providing brief information on the study, then by phone. In cases where the index individuals were not eligible, they were asked whether they would be willing to inform relatives of the study and then inform us as to whether we might contact their relatives directly. The Lund University Ethics Committee approved the study.


A letter including an extensive epidemiologic questionnaire and a written consent form was mailed to women who verbally agreed to participate. The questionnaire included questions on lifestyle and reproductive factors, the use of oral contraceptives and other medications, etc. A trained research nurse collected blood samples between 7:15 am and 12:15 pm and took body measurements twice during each menstrual cycle, days 5-10 and 5-10 days before the predicted onset of the following menstrual period, i.e. cycle days 18-23 in most women. All women were asked to call back with the date of the first day of their next menstrual period. Body measurements included height, weight, waist and hip circumferences, and breast volumes. The plasma and blood cells were separated and frozen at minus 70 degrees Celsius at our laboratory at the Department of Oncology, Lund.

In addition to the 269 healthy women, we also included 40 *BRCA1* and 16 *BRCA2* carriers born between 1950 and 1988, irrespective of their cancer status, who had consented to genetic testing and undergone *BRCA1/2* mutation testing at the laboratory of the Department of Oncology, Lund. Nine of the *BRCA1/2* mutation carriers had a prior breast cancer diagnosis at the time of *BRCA1/2* mutation testing. The total cohort therefore consisted of 325 women from 194 families and the vast majority was Swedish. Some, but not all of these 56 extra *BRCA1/2* carriers had filled-out questionnaires regarding lifestyle factors and prophylactic mastectomies at the Oncogenetic clinic. Our cohort therefore consisted of all *BRCA1* and *BRCA2* carriers from the South Swedish Health Care Region born between 1950 and 1988 with DNA available for SNP testing. All *BRCA1/2* mutation testing in the South Swedish Health Care Region is performed in our laboratory. Mutation testing of the *BRCA1* and *BRCA2* genes was not performed as part of this study. The data on mutation status was obtained from clinical records from the Oncogenetic Clinic of the Department of Oncology in Lund. *BRCA1* and *BRCA2* mutation testing is offered at the Oncogenetic Clinic of the Department of Oncology in Lund if an individual is considered to be at high-risk for breast cancer as defined above. Women are usually not offered testing before age 25. *BRCA* gene mutation carriers included only those with confirmed deleterious alterations, i.e. nonsense or frameshift indel mutations that cause protein

truncation, or known disease-associated missense mutations. Full mutation screening was performed according to denaturing high-performance liquid chromatography (DHPLC), sequencing, and multiplex ligation-dependent probed amplification (MLPA).

#### *Genotyping of AR CAG, GGC and htSNPs*

Genomic DNA was extracted from 300  $\mu$ l of peripheral blood using Wizard, Genomic DNA Purification Kit, (Promega, Madison, WI, USA). The AR polymorphisms CAG and GGC were analyzed as previously described [24]. A CAG allele with <22 repeats was classified as short (S) and with  $\geq$ 22 repeats as long (L). The GGC repeat <17 repeats was classified as short and  $\geq$ 17 as long. The selection of AR htSNPs was based on the six reported SNPs from a Swedish male cohort and these SNPs are estimated to cover over 95% of the haplotypic variation among the men with and without prostate cancer in Sweden [34]. The positions of the htSNPs are presented in the paper by Lindström *et al.* [34], figure 1.



**Figure 1.** Shows the distribution of the htSNPs in the AR gene.

The genotyping of AR htSNPs was performed at Region Skåne Competence Centre (RSKC Malmö), Malmö University Hospital, Malmö, Sweden. The SNPs were genotyped according to the manufacturers' protocol with TaqMan® assay AR rs1337080 by allelic discrimination based on real-time PCR on ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The AR SNPs rs17302090, rs6152, rs7061037, rs5031002, and rs5964607 analyses were performed on a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry on a Sequenom MassARRAY® platform (Sequenom, San Diego, CA, USA), using iPLEX reagents according to the manufacturers' protocol. The Sequenom MassARRAY® designer software was used for multiplex SNP analysis design. For quality control, over 10% of the samples were run in duplicate. The concordance was 100% for the validated samples. The call rates varied between 96.6% and 100%.

#### Construction of haplotypes and diplotypes

Since the AR is located on the X-chromosome and women have two, we constructed diplotypes instead of haplotypes. First each SNP was cross-tabulated against the other five SNPs. This procedure showed that certain combinations did not exist or were very rare. Secondly, we constructed the haplotypes and diplotypes based on the most likely combinations. Thirdly, we compared our results to the haplotypes obtained from the Swedish male cohort and our haplotypes were in agreement with their haplotypes. Rs6152 had 10 missing values. However, the kappa value between rs6152 and rs7061037 was 0.967. For the diplotype analyses we therefore completed the missing rs6152 SNPs based on the rs7061037.

Similarly, rs1337980 was missing for 11 women and based on the remaining five SNPs and most likely haplotypes we were able to complete these missing values. We could, however, not complete one missing value for rs17302090 and two missing values for rs5964607. Diplotype variants present in fewer than five women were classified as rare variants and combined into a single category called rare variants. This group included 18 women with ten different diplotype variants.

#### *Hormone analysis*

Testosterone, androstenedione and DHEAS levels were analyzed for 258 women from EDTA plasma obtained 5-10 days prior to the predicted onset of the next menstrual period, i.e. during menstrual cycle days 18-23 in most women. Testosterone was also analyzed for 257 women from EDTA plasma obtained during menstrual cycle days 5-10.

*Testosterone* in EDTA plasma was measured by electrochemiluminescent immunoassay by Elecsys 1010/2010 Modular analytics E170 analyzer with the Roche Elecsys 1010/2010 (Roche Diagnostics, Mannheim, Germany). This system is based on competitive binding analysis principle using monoclonal antibodies against testosterone. The maximal allowed immunoassay variation was  $\leq 20\%$  for testosterone and according to the manufacturer the detection limits were 0.069-52.00 nmol/L. The limits of detection were defined by the lowest detectable value and the highest value on a master curve,. Values above the curve were reported as  $>52\text{nmol/L}$ .

*Androstenedione* (4-androsten-3,17-dione) and *Dehydroepiandrosterone sulphate* (DHEAS) in EDTA-plasma was analysed with a Coat-a-Count Direct Androstenedione or DHEA-SO<sub>4</sub> radioimmunoassay in-vitro diagnostic test kit (DPC Skafte, Mölndal, Sweden) which is based on competitive binding of androstenedione and DHEAS, respectively, on polyclonal antibodies. MultiCalc Advanced program, version 2.60 linked to the radio count was used to measure the radioactivity. The maximal allowed variation was 10% for androstenedione and the detection limits 0.2-35 nmol/L. For DHEAS, the maximal allowed variation was 13% and the measure limits were 0.3-27.1 micromol/L.

#### *Follow-up*

Women were followed until the development of a first breast cancer according to the regional cancer registries, until the date of a self-reported prophylactic mastectomy or until May 31 2009, whichever came first. The report rate of cancer diagnoses to the Swedish cancer registries is close to a 100 percent. The clinical follow-up of high-risk women includes annual mammograms, ultrasounds and MRIs of the breasts in addition to a physical examination and annual follow-ups of the ovaries by ultrasound, CA-125 and a gynecological examination

#### *Data analysis*

The statistical software PASW Statistics 17.0 and STATA were used for all statistical analyses. Testosterone, androstenedione and DHEAS levels were not normally distributed, and the values were transformed using the natural logarithm (ln) to obtain a better distribution. Multivariate linear regression models were used to compare circulating ln-transformed androgen levels in relation to combined OC use, AR htSNPs and the diplotypes. To investigate whether there were differences according to which type of current OC formula was used, three dummy variables were created for the most common formulas. Another dummy variable was created for progestins with less or no androgenic properties (desogestrel, norgestimate, and drospirenon) compared to those with partially or unclassified androgenic

properties (levonorgestrel, noretisteron, and lynestrenol). The models were standardized for age (29 years), ln-transformed weight (67 kg), waist-to hip ratio (0.77), number of days to next menstrual period (7 days), and for non-current use of combined OCs. For htSNPs, each model also included two dummy variables for heterozygous and homozygous variants of the htSHP. The normal variant was used as reference. For the diplotypes models each model included the diplotype as a dummy variable. The multivariate linear regression models were also adjusted for family clustering by using the cluster option of the regress command in STATA. An interaction term was created between OC use and rare variant diplotypes to test for interactions on androgen levels. The odds of diplotype frequencies were compared between women from families with different mutations, *BRCA1*, *BRCA2*, *BRCAX* or untested family was calculated with Chi-square. Non-standardized geometric means with 95% confidence intervals (CI) for androgen levels for each diplotype were obtained using one-sample t-tests. The diplotype frequencies were compared between women from families with different mutations, *BRCA1*, *BRCA2*, *BRCAX* or untested family. Cox regression models were used to investigate whether the htSNPs or diplotypes were associated with an increased Hazard Ratio of incident breast cancer after 18 years of age. Nominal *P*-values are presented. All *P*-values were two-tailed.



## Results

DNA for genotyping was available for 323 women and hormone analyses were done for 258 women. When we examined AR htSNPs in relation to androgen levels and OC use, we excluded women who were breast-feeding at the time of the blood draw (n=4), women using hormone contraceptives other than combined OCs, e.g. progesterone-only pills, injectable, intrauterine, and implantable hormone contraceptives (n=19) or both (n=1), one woman with missing information on hormonal contraceptive use, as well as women with missing information on number of days to the next menstrual cycle (n=2). The characteristics for the 325 women with genotyping data and the 231 users of combined OCs and non-users with androgen levels are presented in table 1.

**Table 1.** Characteristics of the 325 women included in the study and of the 231 non-users and users of combined OCs with androgen levels available.

	All n=325			Androgen analyses n=231		
	Medians	IQR	n	Medians	IQR	n
Age, yrs	30	25-36	325	29	24-35	231
Year of birth	1969	1964-1975	325	1969	1964-1976	231
Weight, kgs	64.4	58.3-74.0	269	63.8	57.8-72.8	231
Height, cms	168	164-172	269	168	164-172	231
Body mass index	22.8	20.9-25.6	269	22.7	20.8-25.2	231
Waist-to hip ratio	0.76	0.73-0.80	269	0.76	0.73-0.80	231
Age at menarche	13	12-14	312	13	12-14	230
Age at first full term pregnancy	25	22-28	302	24	22-27	124
	<b>Percent</b>			<b>Percent</b>		
Parous	54.4%		305	46.3%		231
Ever use of oral contraception	92.2%		269	91.3%		231
Current use of combined oral contraception	34.2%		269	40.0%		231
Current use of progestin-only pills	4.5%		269	0		231
Current use of other hormonal contraception	3.3%		268	0		231
Current smoker	22.8%		268	23.0%		230
	<b>Number of women</b>			<b>Number of women</b>		
BRCA1 family	134		325	76		231
Mutation carrier	70			23		
Negative	49			44		
Untested	15			9		
BRCA2 family	34		325	13		231
Mutation carrier	23			7		
Negative	7			4		
Untested	4			2		
BRCAX family	112		325	101		231
Untested family	45		325	41		231

IQR interquartile range

### *Androgen levels in relation to combined OC use, AR htSNPs and AR diplotypes*

Standardized androgen levels during cycle days 18-23 were lower among most current OC users compared with non-users. The models were standardized for age (29 years), ln-transformed weight

(67 kg), waist-to hip ratio (0.77), and number of days to next menstrual period (7 days). In current OC users, compared with non-users, standardized geometric mean testosterone levels were 1.01 versus 1.59 nmol/L, androstenedione levels were 5.91 versus 9.08 nmol/L, and DHEAS levels were 3.16 versus 4.51  $\mu$ mol/L (all  $P$ s<0.0001). Thirteen different formulas of combined OCs were used. There were no significant differences in testosterone, androstenedione or DHEAS levels according to the androgenic properties of the progestin. The three most common formulas were Desolett® (n=24; monophasic pill containing ethinylestradiol and desogestrel), Follimin® (n=17; monophasic pill containing ethinylestradiol and levonorgestrel), and Trionetta® (n=10; triphasic pill containing ethinylestradiol and levonorgestrel). There were no significant differences in testosterone, androstenedione or DHEAS levels between women using the above most common formulas and other formulas.

The individual htSNPs were not associated with androstenedione or DHEAS levels among all women, current OC users or non-users (data not shown). Only one htSNP, heterozygous rs5031002, was associated with lower standardized testosterone levels among non-users ( $P=0.03$ ), table 2.

We then analyzed androgen levels during cycle days 18-23 in relation to diplotypes in all women, and stratified for current combined OC use, figure 2. Only rare variant diplotypes were associated with testosterone levels, but not with androstenedione or DHEAS levels. The rare variant diplotypes were associated with non-significantly higher testosterone levels among current OC users compared with the other diplotypes (adjusted  $P=0.067$ ) and lower testosterone levels among non-users compared with the other diplotypes (adjusted  $P=0.045$ ). There was a strong interaction between the rare variant diplotypes and combined OC use on testosterone levels during cycle days 18-23, ( $\beta=0.61$ ;  $P_{\text{interaction}}=0.011$ ), adjusted for age, ln-transformed weight, waist-to hip ratio, and number of days to next menstrual period. The interaction between the rare diplotype variants and combined OC use on testosterone levels was also present during menstrual cycle days 5-10 ( $\beta=0.44$ ; adjusted  $P_{\text{interaction}}=0.048$ ). When we adjusted the models for family clustering, the rare variant diplotypes were still associated with higher testosterone levels during cycle days 18-23 among current OC users compared with the other diplotypes (adjusted  $P<0.001$ ) and lower testosterone levels among non-users compared with the other diplotypes (adjusted  $P=0.012$ ). Similarly, the interaction between the rare variant diplotypes and combined OC use on testosterone levels during cycle days 18-23 and during cycle days 5-10 remained significant after adjustment for family clustering (adjusted  $P_{\text{interaction}}<0.001$  and adjusted  $P_{\text{interaction}}=0.003$ ; respectively).

### ***AR diplotypes in relation to CAG and GGC***

As previously reported [24], the AR microsatellite CAG and GGC repeat lengths were genotyped for a subset of the cohort (254 and 253 young women, respectively). The frequencies of CAG and GGC genotypes in relation to AR diplotypes are shown in figure 3. The AR CAG (L/L) genotype did not co-segregate with GGAAGC/GAGGGT. The AR CAG (S/S) genotype did not co-segregate with GGAAGC/GGAAAC. AR GGC S/S genotype co-segregated only with GGAAGC/GGAAGC, the rare variant diplotypes, and GGAAGC/AAGAGT diplotypes. Since OC users had lower testosterone levels than non-users with all AR CAG and GGC genotypes, except for the GGC (S/S) genotype as reported in our previous study, we combined the three diplotypes that co-segregated with the GGC (S/S) genotype. However, these three diplotypes were not associated with testosterone levels in current OC users or non-users when compared with the remaining three diplotypes.

**Figure 2**

Geometric means with 95% CI of testosterone in relation to AR diplotypes in A) all women, B) non-users, and C) current OC users during menstrual cycle days 18-23. The number of women with each diplotype is indicated. The squares indicate non-standardized testosterone levels and the round dots indicate testosterone levels standardized for age (29 years), ln-transformed weight (67 kg), waist-to-hip ratio (0.77), number of days to next menstrual period (7 days), and for non-current use of combined OCs. In A) the continuous line represents the geometric mean for all women, and in B) and C) the dotted line represents the geometric mean for all women and the continuous line the geometric mean for non-users and current OC users, respectively. The rare variant diplotypes were associated with non-significantly higher testosterone levels among current OC users compared with the other diplotypes (adjusted  $P=0.067$ ) and lower testosterone levels among non-users compared with the other diplotypes (adjusted  $P=0.045$ ). There was an interaction between the rare variant diplotypes and combined OC use on testosterone levels during cycle days 18-23, ( $\beta=0.61$ ;  $P_{\text{interaction}}=0.011$ ), adjusted for age, ln-transformed weight, waist-to-hip ratio, and number of days to next menstrual period.





Table 2. AR ht SNPs in relation to standardized testosterone levels. The levels were standardized for age (29 years), ln-transformed weight (67 kg), waist-to hip ratio (0.77), and number of days to next menstrual period (7 days). In the model including all women the levels were standardized to non-current use of combined OCs. Heterozygous and homozygous variants of the htSNPs were entered as dummy variables. The normal variant was used as reference.


AR htSNP	Genotype	All women		N (n=231)	All women Testosterone nmol/l	P-value	N (n=143)	No OC use Testosterone nmol/l	P-value	Current OC use		
		N (n=325)	%							N (n=88)	Testosterone nmol/l	P-value
rs17302090	GG	279	85.8	197	1.59	ref	114	1.60	ref	83	1.04	ref
	GA	41	12.6	29	1.68	0.48	25	1.65	0.69	4	1.16	0.68
	AA	2	0.6	2	1.17	0.30	2	1.11	0.18	0	-	
	Missing	3	0.9	3			2			1		
rs6152	GG	235	72.3	171	1.58	ref	102	1.59	ref	69	1.00	ref
	GA	72	22.2	44	1.66	0.46	32	1.70	0.39	12	0.97	0.79
	AA	6	1.8	5	1.41	0.53	4	1.21	0.16	1	1.74	0.22
	Missing	12	3.7	11			5			6		
rs7061037	AA	233	71.7	170	1.60	ref	100	1.59	ref	70	1.03	ref
	AG	84	25.8	54	1.67	0.45	37	1.66	0.56	17	1.05	0.89
	GG	6	1.8	5	1.19	0.11	5	1.17	0.08	0	-	
	Missing	2	0.6	2			1			1		
rs1337080	AA	268	82.5	198	1.61	ref	125	1.57	ref	73	1.02	ref
	AG	44	13.5	26	1.65	0.80	15	1.63	0.72	11	1.02	0.98
	GG	0	0	0	-		0	-		0	-	
	Missing	13	4.0	7			3			4		
rs5031002	GG	307	94.5	215	1.60	ref	134	1.60	ref	81	1.01	ref
	GA	16	4.9	14	1.42	0.31	8	1.18	0.03	6	1.11	0.64
	AA	0	0	0	-		0	-		0	-	
	Missing	2	0.6	2			1			1		
rs5964607	CC	217	66.8	161	1.55	ref	97	1.55	ref	64	1.02	ref
	CT	97	29.8	61	1.70	0.13	40	1.68	0.29	21	1.13	0.37
	TT	7	2.2	6	1.24	0.18	5	1.16	0.09	1	1.20	0.72
	Missing	4	1.2	3			1			2		




### Figure 3

A) CAG repeat length frequencies among women (n=254) for each *AR* diplotype. The CAG alleles with <22 were classified as short (S) and  $\geq 22$  as long (L). The *AR* CAG (L/L) genotype did not co-segregate with GGAAGC/GAGGGT. The *AR* CAG (S/S) genotype did not co-segregate with GGAAGC/GGAAGT.

B) GGC repeat length frequencies among women (n=253) for each *AR* diplotype. The GGC alleles with <17 were classified as short (S) and  $\geq 17$  as long (L). *AR* GGC S/S genotype co-segregated only with GGAAGC/GGAAGC, the rare variant diplotypes, and GGAAGC/AAGAGT diplotypes.

A Diplotype frequencies in *BRCA1*, *BRCA2* and *BRCAX* families

No of women	All	<i>BRCA1</i>	<i>BRCA2</i>	<i>BRCAX</i>
All	201	42	32	15
<i>BRCA1</i>	74	20	17	5
<i>BRCA2</i>	22	3	4	3
<i>BRCAX</i>	74	13	8	6

B Diplotype frequencies in the first included woman from *BRCA1*, *BRCA2* and *BRCAX* families

No of women	All	<i>BRCA1</i>	<i>BRCA2</i>	<i>BRCAX</i>
All	124	20	18	10
<i>BRCA1</i>	29	8	10	3
<i>BRCA2</i>	13	3	2	2
<i>BRCAX</i>	52	5	4	4

### Figure 4

A) Frequency distribution of AR diplotypes among all women (n=320) from *BRCA1*, *BRCA2* and *BRCAX* families. In the *BRCA1* families, the odds of having a GGAAGC/GGAAGC diplotype was lower than in other families, irrespective of mutation status, OR 0.63 (95%CI 0.40-1.00;  $P=0.051$ ). The GGAAGC/GGAAAC was not present in women belonging to *BRCA2* families. None of the other diplotypes was associated with *BRCA1/2* or *BRCAX* family status.

B) Frequency distribution of AR diplotypes for the women first enrolled from *BRCA1*, *BRCA2* and *BRCAX* families (n=192). The odds of having a GGAAGC/GGAAGC diplotype was lower in women from *BRCA1* compared to women from the other family types, OR 0.41 (95%CI 0.22-0.78;  $P=0.005$ ), whereas the odds of having a GGAAGC/AAGAGT diplotype was higher in *BRCA1* families OR 3.28 (95%CI 1.22-8.81;  $P=0.014$ ). The GGAAGC/GGAAAC was not present in women belonging to *BRCA2* families. None of the other diplotypes was associated with *BRCA1/2* or *BRCAX* family status. The GGAAGC/GGAAAC was not present in women belonging to *BRCA2* families.



***AR diplotypes in relation to BRCA-family status***

The frequency distribution of AR diplotypes among all women and women from *BRCA1*, *BRCA2* and *BRCAX* families, and among the women first enrolled from each family (n=192) are presented in figure 4. In the *BRCA1* families, the GGAAGC/GGAAGC diplotype was less common than in other families, irrespective of mutation status, OR 0.63 (95%CI 0.40-1.00;  $P=0.051$ ). Since some women belonged to the same families, we restricted the analyses to include only to the first enrolled woman from each family. In this subgroup analysis, the odds of having a GGAAGC/GGAAGC diplotype was lower in women from *BRCA1* compared to women from the other family types, OR 0.41 (95%CI 0.22-0.78;  $P=0.005$ ), whereas the odds of having a GGAAGC/AAGAGT diplotype was higher in *BRCA1* families OR 3.28 (95%CI 1.22-8.81;  $P=0.014$ ). None of the other diplotypes was associated with *BRCA1/2* or *BRCAX* family status.

Among the 325 women, 23 have developed breast cancer after age 18 years. Eleven incident cancers were found in the original cohort of 269 women, three incident cancers were diagnosed after mutation testing in the additional 56 *BRCA1/2* mutation carriers and nine of the carriers had a breast cancer diagnosis prior to mutation testing. Thirteen women were known *BRCA1* mutation carriers, five were known *BRCA2* mutation carriers, four belonged to *BRCAX* families, and one woman belonged to an untested family. The median age at diagnosis was 39 years (range 28 to 50 years). Breast cancer was not significantly associated with any of the htSNPs or the diplotypes. Of the 23 breast cancer cases, 17 women had the most common GGAAGC/GGAAGC diplotype, three women had the GGAAGC/AAGAGT diplotype, two women had the GGAAGC/GAGGGT diplotype, and one woman had a rare variant diplotype. The hazard of an incident breast cancer was non-significantly higher with the three diplotypes that co-segregated with the GGC (S/S) genotype compared with the remaining diplotypes, HR 2.79 (95% CI 0.65-11.99;  $P=0.17$ ), adjusted for *BRCA1* and *BRCA2* mutation status.



## Discussion

This is the first study to examine AR htSNP diplotype data in relation to *in vivo* androgen levels, combined OC use, CAG and GGC genotypes, and BRCA1/2 and BRCA2 family status in young women from breast cancer high-risk families. Our main findings were that OC status affected testosterone levels differently among women who had a rare variant diplotype compared to women with other diplotypes, and that the odds of having the most common diplotype GGAAGC/GGAAGC was lower in BRCA1 families compared to other families.

In the current study, there was a strong interaction between the rare variant diplotypes and combined OC use on testosterone levels during both cycle days 18-23 and cycle days 5-10. Women with rare variant diplotypes may not be helped by combined OC treatment of acne or other androgen dependent conditions, but this needs to be confirmed in other studies. Since many of the women were from same families, we expected that some of the diplotype variants would be more common among women from the same families and the testosterone levels would differ between the families. We therefore adjusted the models for family clustering. Surprisingly, the interaction between rare variant diplotypes and combined OC use on testosterone levels became stronger after adjustment for family clustering. However, there were few women with the rare variant diplotypes and this group consisted of ten different diplotype variants. There is therefore a risk of an inflated finding due to small-sample error. An alternative explanation would be that the rare variant diplotypes actually do reflect rare AR genotypes with altered functionality due to other functional polymorphisms and different androgen levels. We found that androgen levels during cycle days 18-23 were lower among most current OC users compared with non-users, which is in line with previous findings [24, 29]. OCs suppress gonadotropins, which leads to lower endogenous androgen and estrogen production in the ovaries [11, 35, 36].

It is easier to perform high throughput genotyping of htSNPs than of microsatellites. Since some polymorphisms in the AR have been linked to testosterone levels in both women and men, as well as breast and prostate cancer [20, 21, 23, 25-28, 37, 38] it is possible that the htSNPs that co-segregate with these polymorphisms may modify androgen levels and breast cancer risk. It is also possible that young women who have higher testosterone levels during OC use belong to the subgroup of women who are at higher risk for early-onset breast cancer if they use OCs. While it has been established that OC use is associated with higher breast cancer risk in the general population [30], as well as in women from high-risk families [31, 32] and that ethinylestradiol is carcinogenic to humans [39], the role of testosterone in breast cancer is less clear [3, 6, 7, 11]. In a previous study, we found a significant interaction between the cumulative number of short GGC alleles and testosterone levels among current OC users during cycle days 5-10 and a near significant interaction during cycle days 18-23 [24]. The testosterone levels were increasing with increasing number of short GGC alleles among current OC users during both cycle phases [24]. In the current study, GGC (S/S) genotype co-segregated only with rare variant diplotypes and two other diplotypes. However, only the rare variant diplotypes were associated with testosterone levels in the current study. We do not know whether this interaction was driven by the rare variant diplotypes or the GGC genotype.

The individual AR htSNPs were not associated with androstenedione or DHEAS levels among current OC users or non-users. Only one AR htSNPs (rs5031002) was associated with lower testosterone levels among non-users. Due to the large number of analyses, this may be due to chance. The selected htSNPs were from a large Swedish male cohort of prostate cancer patients and their controls, and were estimated to cover over 95% of the genetic variation in the AR gene [34]. After construction of the haplotypes and diplotypes in the current study, we had the same haplotypes as Lindström *et al.* [34]. However, the association between haplotypes and long AR CAG allele in the study by Lindström *et al.* [34] was not the same as in our study. In the study by Lindström *et al.* a

long CAG allele co-segregated only with GGAAGC and GGAAGT haplotypes, while the short CAG allele was present among individuals with all haplotypes [34], in contrast to our results. Lindström *et al.* [34] did not genotype the GGC repeat and our study is the first one to report that the GGC S/S genotype co-segregated with three AR diplotype variants.

We also studied the frequency of the different AR diplotypes in relation to BRCA family status and among the first women enrolled from each family (BRCA1, BRCA2 and BRCAX families). The odds of having the most common diplotype in the whole study population (GGAAGC/GGAAGC) was lower in the BRCA1 families, irrespective of mutation status, than in the other families. The odds of having the GGAAGC/AAGAGT was higher in BRCA1 families. This diplotype had the highest testosterone levels, although not statistically significant. Since the GGAAGC/GGAAGC was a less common diplotype among BRCA1 families than among other families, one may hypothesize that this combination confers some survival disadvantage. In the study by Lindström *et al.* both the most common AR haplotype (GGAAGC) and the AAGAGT haplotypes were associated with increased prostate cancer risk [34]. Another study showed that CAG with  $\geq 28$  repeats was associated with younger age at breast cancer diagnosis [28]. In our study, the most common AR diplotype GGAAGC/GGAAGC was more commonly represented among women with over 28 CAG repeats (data not shown). No significant association was found between incident breast cancer and the different AR diplotypes or individual htSNPs. However, the number of cases with incident breast cancer was low (23 of 325 women). Moreover, we only had information on OC use for half of the cases. A recent large study investigated the relationship between AR htSNPs, haplotypes and CAG repeats among 5603 breast cancer cases and 7480 controls and no association was found between any genetic variants and breast cancer [33].

Women are mosaics for two different cell types, cells with an active X-chromosome from the mother and cells with an active X-chromosome from the father. Skewed X-inactivation is arbitrarily defined as deviation from the binomial inactivation, with 80% or more of the cells having preferential inactivation of only one X-chromosome. Although the inactivation is thought to be permanent and passed on to the cell descendants, the pattern changes with age and older women have increased frequency of skewed inactivation in peripheral blood cells [40]. One study reported a higher frequency of skewed X-inactivation in young breast cancer patients with a family history of breast cancer, but no BRCA1/2 mutations, compared to controls. However, skewed X-inactivation frequency did not differ significantly between BRCA1/2 mutation carriers and age-matched healthy controls [41]. We did not perform X-inactivation analysis in our study. All diplotype variants, except for a subgroup of the rare variants, contained at least one copy of the most common haplotype.

There are limitations to our study. There were few incident breast cancer cases during follow-up and a larger cohort with complete information on OC use would have been preferable. However, our cohort consisted of all BRCA1/2 mutation carriers from the South Swedish Health Care Region born between 1950 and 1988 with DNA available for SNP testing. We also lacked information on androgen dependent conditions such as acne, and were therefore unable to assess whether AR diplotypes were associated with these conditions. Women have low testosterone levels. Compared to the assays used in the current study, more sensitive experimental methods based on chromatography followed by tandem mass spectrometry have since been developed [3].

In conclusion, this is the first study to examine AR htSNP diplotype data in relation to *in vivo* androgen hormone levels, combined OC use, CAG and GGC repeat lengths, and BRCA1/2 and BRCAX family status. Neither individual AR htSNPs nor diplotypes tagged for CAG or GGC genotypes. Combined OC use affected testosterone levels differently among women who had a rare variant diplotype compared to women with other diplotypes, but this finding needs confirmation in

independent cohorts. Apart from the rare variant diplotypes, there was no significant association between *AR* diplotypes and androgen or proandrogen levels. The most common diplotype was less common in families with *BRCA1* mutations and the clinical significance of this finding needs elucidation. Since testosterone levels are not affected the same way by combined OC use among all women, young women who have higher testosterone levels during combined OC use may belong to the subgroup of women who will not be helped by combined OCs for treatment of androgen dependent conditions and may be at higher risk for early-onset breast cancer. Whether these women can be identified with *AR* genotyping needs to be confirmed in an independent cohort.

**Author contributions**

Maria Hietala provided background information, performed the statistical analyses and prepared the manuscript. Maria Henningson abstracted data and clinical information on study participants, performed data entry and provided comments on the manuscript. Therese Törngren performed the CAG and GGC genotype analyses. Håkan Olsson provided background information and comments on the manuscript. Helena Jernström initiated this study, provided background information, and supervised the statistical analyses and the writing of the manuscript. All authors approved the final manuscript.

**Acknowledgments**

We thank our research nurses Kerstin Nilsson, Monica Pehrsson, Anita Schmidt-Casslén for assistance with body measurements and blood drawing and Johanna Wagenius, Johanna Frenander, Helen Sundberg, Malin Sternby, and Susanna Holmquist for their assistance with recruitment. We thank Erika Bågeman for validation of the genetic analyses. We also thank Dr. Eric T. Dryver for proofreading the manuscript, and Dr. Pär-Ola Bendahl for his assistance with the statistical analyses on family clustering.

**Funding**

This study was supported by grants from Vetenskapsrådet (the Swedish Research Council, K2001-27GX-14120-01A and K2008-68X20802-01-3), the Medical Faculty, Lund University, the Mrs. Berta Kamprad's Foundation, the Gunnar Nilsson Foundation, the South Swedish Health Care Region (Region Skåne), Lund Hospital Fund and the Swedish Cancer Society.

## References

- [1] S. Karrer-Voegeli, F. Rey, M.J. Reymond, J.Y. Meuwly, R.C. Gaillard, F. Gomez, Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism *Medicine (Baltimore)* 88 (2009) 32-45.
- [2] F.Z. Stanczyk, Diagnosis of hyperandrogenism: biochemical criteria *Best Pract Res Clin Endocrinol Metab* 20 (2006) 177-191.
- [3] L.R. Schover, Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? *Fertil Steril* 90 (2008) 129-140.
- [4] W. Somboonporn, S.R. Davis, Testosterone effects on the breast: implications for testosterone therapy for women *Endocr Rev* 25 (2004) 374-388.
- [5] F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.X. Lin, G. Pelletier, Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone *Endocr Rev* 24 (2003) 152-182.
- [6] A. Micheli, P. Muti, G. Secreto, V. Krogh, E. Meneghini, E. Venturelli, S. Sieri, V. Pala, F. Berrino, Endogenous sex hormones and subsequent breast cancer in premenopausal women *Int J Cancer* 112 (2004) 312-318.
- [7] R. Kaaks, F. Berrino, T. Key, S. Rinaldi, L. Dossus, C. Biessy, G. Secreto, P. Amiano, S. Bingham, H. Boeing, H.B. Bueno de Mesquita, J. Chang-Claude, F. Clavel-Chapelon, A. Fournier, C.H. van Gils, C.A. Gonzalez, A.B. Gurrea, E. Critselis, K.T. Khaw, V. Krogh, P.H. Lahmann, G. Nagel, A. Olsen, N.C. Onland-Moret, K. Overvad, D. Palli, S. Panico, P. Peeters, J.R. Quiros, A. Roddam, A. Thiebaut, A. Tjonneland, M.D. Chirlaque, A. Trichopoulou, D. Trichopoulos, R. Tumino, P. Vineis, T. Norat, P. Ferrari, N. Slimani, E. Riboli, Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) *J Natl Cancer Inst* 97 (2005) 755-765.
- [8] T. Key, P. Appleby, I. Barnes, G. Reeves, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies *J Natl Cancer Inst* 94 (2002) 606-616.
- [9] S.A. Missmer, A.H. Eliassen, R.L. Barbieri, S.E. Hankinson, Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women *J Natl Cancer Inst* 96 (2004) 1856-1865.
- [10] A. Zeleniuch-Jacquotte, P.F. Bruning, J.M. Bonfrer, K.L. Koenig, R.E. Shore, M.Y. Kim, B.S. Pasternack, P. Toniolo, Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women *Am J Epidemiol* 145 (1997) 1030-1038.
- [11] C. Dimitrakakis, C. Bondy, Androgens and the breast *Breast Cancer Res* 11 (2009) 212.
- [12] S.N. Birrell, R.E. Hall, W.D. Tilley, Role of the androgen receptor in human breast cancer *J Mammary Gland Biol Neoplasia* 3 (1998) 95-103.
- [13] H. Yu, X.O. Shu, B.D. Li, Q. Dai, Y.T. Gao, F. Jin, W. Zheng, Joint effect of insulin-like growth factors and sex steroids on breast cancer risk *Cancer Epidemiol Biomarkers Prev* 12 (2003) 1067-1073.
- [14] The National Board of Health And Welfare, Cancer Incidence In Sweden 2008, Stockholm, Sweden, 2009.
- [15] S.A. Narod, W.D. Foulkes, BRCA1 and BRCA2: 1994 and beyond *Nat Rev Cancer* 4 (2004) 665-676.
- [16] M. Lacroix, G. Leclercq, The "portrait" of hereditary breast cancer *Breast Cancer Res Treat* 89 (2005) 297-304.
- [17] R.G. Dumitrescu, I. Cotarla, Understanding breast cancer risk -- where do we stand in 2005? *J Cell Mol Med* 9 (2005) 208-221.
- [18] A.R. Venkitaraman, Cancer susceptibility and the functions of BRCA1 and BRCA2 *Cell* 108 (2002) 171-182.

- [19] S. Yeh, Y.C. Hu, M. Rahman, H.K. Lin, C.L. Hsu, H.J. Ting, H.Y. Kang, C. Chang, Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells *Proc Natl Acad Sci U S A* 97 (2000) 11256-11261.
- [20] N.M. Suter, K.E. Malone, J.R. Daling, D.R. Doody, E.A. Ostrander, Androgen receptor (CAG)<sub>n</sub> and (GGC)<sub>n</sub> polymorphisms and breast cancer risk in a population-based case-control study of young women *Cancer Epidemiol Biomarkers Prev* 12 (2003) 127-135.
- [21] L. Westberg, F. Baghaei, R. Rosmond, M. Hellstrand, M. Landen, M. Jansson, G. Holm, P. Bjorntorp, E. Eriksson, Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women *J Clin Endocrinol Metab* 86 (2001) 2562-2568.
- [22] L. Ibanez, K.K. Ong, N. Mongan, J. Jaaskelainen, M.V. Marcos, I.A. Hughes, F. De Zegher, D.B. Dunger, Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism *J Clin Endocrinol Metab* 88 (2003) 3333-3338.
- [23] I.S. Brum, P.M. Spritzer, F. Paris, M.A. Maturana, F. Audran, C. Sultan, Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women *J Soc Gynecol Investig* 12 (2005) 135-141.
- [24] M. Hietala, T. Sandberg, A. Borg, H. Olsson, H. Jernström, Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women *Hum Reprod* 22 (2007) 83-91.
- [25] Y. Giguere, E. Dewailly, J. Brisson, P. Ayotte, N. Laflamme, A. Demers, V.I. Forest, S. Dodin, J. Robert, F. Rousseau, Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population *Cancer Res* 61 (2001) 5869-5874.
- [26] A. Liede, W. Zhang, M.L. De Leon Matsuda, A. Tan, S.A. Narod, Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines *Cancer Epidemiol Biomarkers Prev* 12 (2003) 848-852.
- [27] C.A. Haiman, M. Brown, S.E. Hankinson, D. Spiegelman, G.A. Colditz, W.C. Willett, P.W. Kantoff, D.J. Hunter, The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study *Cancer Res* 62 (2002) 1045-1049.
- [28] T.R. Rebbeck, P.W. Kantoff, K. Krithivas, S. Neuhausen, M.A. Blackwood, A.K. Godwin, M.B. Daly, S.A. Narod, J.E. Garber, H.T. Lynch, B.L. Weber, M. Brown, Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat *Am J Hum Genet* 64 (1999) 1371-1377.
- [29] H.C. Jernström, H. Olsson, Å. Borg, Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients *Eur J Cancer Prev* 6 (1997) 330-340.
- [30] Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer *Lancet* 347 (1996) 1713-1727.
- [31] H. Jernström, T. Sandberg, E. Bageman, A. Borg, H. Olsson, Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families *Br J Cancer* 92 (2005) 857-866.
- [32] S.A. Narod, M.P. Dube, J. Klijn, J. Lubinski, H.T. Lynch, P. Ghadirian, D. Provencher, K. Heimdal, P. Moller, M. Robson, K. Offit, C. Isaacs, B. Weber, E. Friedman, R. Gershoni-Baruch, G. Rennert, B. Pasini, T. Wagner, M. Daly, J.E. Garber, S.L. Neuhausen, P. Ainsworth, H. Olsson, G. Evans, M. Osborne, F. Couch, W.D. Foulkes, E. Warner, C. Kim-Sing, O. Olopade, N. Tung, H.M. Saal, J. Weitzel, S. Merajver, M. Gauthier-Villars, H. Jernström, P. Sun, J.S. Brunet, Oral

contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers *J Natl Cancer Inst* 94 (2002) 1773-1779.

- [33] D.G. Cox, H. Blanche, C.L. Pearce, E.E. Calle, G.A. Colditz, M.C. Pike, D. Albanes, N.E. Allen, P. Amiano, G. Berglund, H. Boeing, J. Buring, N. Burt, F. Canzian, S. Chanock, F. Clavel-Chapelon, H.S. Feigelson, M. Freedman, C.A. Haiman, S.E. Hankinson, B.E. Henderson, R. Hoover, D.J. Hunter, R. Kaaks, L. Kolonel, P. Kraft, L. LeMarchand, E. Lund, D. Palli, P.H. Peeters, E. Riboli, D.O. Stram, M. Thun, A. Tjonneland, D. Trichopoulos, M. Yeager, A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) *Breast Cancer Res* 8 (2006) R54.
- [34] S. Lindström, F. Wiklund, H.O. Adami, K.A. Balter, J. Adolfsson, H. Gronberg, Germline genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development *Cancer Res* 66 (2006) 11077-11083.
- [35] F. Modugno, Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review *Am J Epidemiol* 159 (2004) 319-335.
- [36] B.R. Carr, N.A. Breslau, C. Givens, W. Byrd, C. Barnett-Hamm, P.B. Marshburn, Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study *J Clin Endocrinol Metab* 80 (1995) 1169-1178.
- [37] K. Krithivas, S.M. Yurgalevitch, B.A. Mohr, C.J. Wilcox, S.J. Batter, M. Brown, C. Longcope, J.B. McKinlay, P.W. Kantoff, Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men *J Endocrinol* 162 (1999) 137-142.
- [38] C. Ntais, A. Polycarpou, A. Tsatsoulis, Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes *Eur J Endocrinol* 149 (2003) 469-477.
- [39] World Health Organization International Agency on Cancer, Hormonal contraception and post-menopausal hormonal therapy, IARC Press, Lyon, France, 1999.
- [40] K.H. Orstavik, Skewed X inactivation in healthy individuals and in different diseases *Acta Paediatr Suppl* 95 (2006) 24-29.
- [41] M. Kristiansen, G.P. Knudsen, P. Maguire, S. Margolin, J. Pedersen, A. Lindblom, K.H. Orstavik, High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer *J Med Genet* (2005).